Whole pelvis radiotherapy (WPRT) may improve treatment outcomes among patients with intermediate- or high-risk prostate cancer compared with prostate-only radiotherapy (PORT), a new study suggests. A team led by Peter J. Hoskin, MD, PhD, of Southampton General Hospital in Southampton, UK, compared the approaches in a prospective cohort study that included 812 men with intermediate-…
Ultra-hypofractionated stereotactic body radiotherapy cuts treatment from 2 months to 2 weeks
Study findings suggest that many men can be spared radiation therapy following radical prostatectomy for high-risk prostate cancer.
In a study, select CRPC patients who benefited from initial radium‐223 therapy but later had bone progression were re-challenged with additional radium-223 injections and had no serious adverse effects.
Adjuvant docetaxel given to men who underwent radiotherapy for intermediate- or high-risk prostate cancer and who were on androgen deprivation therapy did not lower their risk of PSA progression, a study found.
In a study, radical prostatectomy for men with Gleason 8-10 prostate cancer and low PSA levels was associated with a lower death risk compared with external beam radiation therapy with or without brachytherapy.
Ultra-hypofractionated and conventionally fractionated radiotherapy for intermediate- or high-risk prostate cancer are associated with similar 5-year failure-free survival rates, a randomized phase 3 trial found.
Using EBRT alone or ADT alone for high-risk localized prostate cancer is associated with worse survival outcomes.
In a study, radiation delivered to the primary prostate tumor in men with metastatic castration-resistant prostate cancer was associated with a 74% decreased risk of death from any cause.
In a study with a follow-up period of 18 years, men treated with any other modality but radical prostatectomy had higher prostate cancer death risks.
